Sanofi India Issues Notice for Transfer of Unclaimed Shares to IEPF Authority

2 min read     Updated on 14 Mar 2026, 12:50 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Sanofi India Limited has issued a mandatory notice for transfer of unclaimed equity shares to the IEPF Authority. The company published newspaper advertisements on March 14, 2026, notifying shareholders who haven't claimed dividends for seven consecutive years starting from FY 2018. Affected shareholders have until June 13, 2026, to claim their dividends and shares before automatic transfer to IEPF. The company has provided contact details for its registrar MUGF Intime India Private Limited for shareholder assistance.

35018442

*this image is generated using AI for illustrative purposes only.

Sanofi India Limited has issued a public notice regarding the mandatory transfer of equity shares to the Investor Education and Protection Fund (IEPF) Authority for shareholders who have not claimed their dividends for seven consecutive years or more.

Regulatory Compliance Notice

The company has published newspaper advertisements on March 14, 2026, in Business Standard (English) and Sakal (Marathi) newspapers, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This notice addresses shareholders whose shares are liable for transfer to the IEPF as per Section 124(6) of the Companies Act, 2013.

Transfer Requirements and Timeline

Under the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, companies must transfer all shares to the IEPF demat account where dividends have remained unclaimed for seven consecutive years or more.

Key Details: Information
Notice Date: March 13, 2026
Publication Date: March 14, 2026
Deadline for Claims: June 13, 2026
Starting Period: Final dividend for FY 2018
Affected Dividends: All subsequent declared dividends

Sanofi India has sent separate communications dated March 13, 2026, to all affected shareholders who have not encashed their final dividend for financial year 2018 and subsequent dividends declared by the company.

Shareholder Action Required

Shareholders are requested to forward requisite documents to either the company or its Registrar and Transfer Agent, MUGF Intime India Private Limited (formerly Link Intime India Private Limited), to claim unclaimed dividend amounts and shares. A comprehensive list of shareholders who have not encashed dividends for seven consecutive years is available on the company's website.

Recovery Process for Transferred Shares

Once shares are transferred to IEPF, all future benefits will be issued in favor of the IEPF Authority. However, shareholders can reclaim both unclaimed dividends and transferred shares by:

  • Making an online application in prescribed e-form IEPF-5
  • Obtaining an entitlement letter from the company
  • Submitting required documents as enumerated in the e-form
  • Following the procedure outlined on the IEPF website at www.iepf.gov.in

Contact Information

For queries related to this matter, shareholders can contact:

Contact Details: Information
Registrar: MUGF Intime India Private Limited
Address: C-101, Embassy 247, L.B.S Marg, Vikhroli (West), Mumbai - 400 083
Phone: +91 81081 16767
Email: investor.helpdesk@in.mpms.mugf.com

The notice emphasizes that no claims will be entertained against the company once shares are transferred to IEPF, making it crucial for eligible shareholders to act before the June 13, 2026 deadline.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-0.65%-5.81%-15.86%-32.78%-39.59%-56.28%

Sanofi India Limited Releases Complete Transcript of Q4FY26 Investor Call

1 min read     Updated on 05 Mar 2026, 03:49 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Sanofi India Limited has released the complete transcript of its investor/analysts call held on February 26, 2026, discussing Q4FY26 and FY25 financial results. The transcript was submitted to stock exchanges on March 5, 2026, following regulatory requirements under SEBI regulations, with management highlighting business transformation initiatives and diabetes portfolio growth.

33761102

*this image is generated using AI for illustrative purposes only.

Sanofi India Limited has released the complete transcript of its investor/analysts call held on February 26, 2026, discussing financial results for Q4FY26 and the year ended December 2025. The pharmaceutical company submitted the transcript to stock exchanges on March 5, 2026, following the earlier upload of the video recording.

Regulatory Compliance and Documentation

The transcript submission was made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was signed by Haresh Vala, Company Secretary & Compliance Officer (Membership No: A18246), and digitally authenticated on March 5, 2026, at 15:31:40 +05'30'.

Parameter: Details
Call Date: February 26, 2026
Call Time: 4:00 pm
Discussion Topic: Q4FY26 and FY25 Financial Results
Period Covered: Quarter and year ended December 31, 2025
Transcript Submission: March 5, 2026
Recording Location: Company website - Analyst/Investor Meet section

Management Participation

The investor conference call was attended by key management personnel including Mr. Deepak Arora (Managing Director), Mr. Rachid Ayari (Whole-Time Director and Chief Financial Officer), and Mr. Haresh Vala (Company Secretary). The call was moderated and included a comprehensive Q&A session with investors and analysts.

Key Discussion Areas

The transcript reveals detailed discussions on the company's business transformation journey, financial performance, and strategic initiatives. Management highlighted the pivotal transformation undertaken to modernize the business model, positioning the company as an R&D-driven, AI-enabled biopharma organization with focus on patient centricity and digital capabilities.

Business Segment: Performance Highlights
Diabetes Portfolio: Plus 6% growth in insulin overall for full year
Q4 Performance: 11% growth in diabetes segment
Partnership Business: Stabilizing with growth expectations
Market Position: Lantus maintains 31% market leadership in basal segment

Accessibility and Transparency

Both the video recording and transcript are now available on Sanofi India's official website in the Analyst/Investor Meet section, ensuring comprehensive access to stakeholders. This dual documentation approach demonstrates the company's commitment to transparency and regulatory compliance in investor communications.

Historical Stock Returns for Sanofi

1 Day5 Days1 Month6 Months1 Year5 Years
-0.65%-5.81%-15.86%-32.78%-39.59%-56.28%

More News on Sanofi

1 Year Returns:-39.59%